Figure 2.

Potential therapeutic options in PMBCL. Prospective studies to establish optimal first and subsequent line treatment and monitoring strategies are currently ongoing. This schema outlines a range of options that are either currently available or under evaluation (such as ctDNA). ASCT, autologous stem cell transplant; CR, complete response; ctDNA, circulating tumour DNA; DA‐EPOCH‐R, dose‐adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, plus rituximab; EOT, end of treatment; PD‐1, programmed cell death 1 (also termed PDCD1); PET, positron emission tomography; PMBCL, primary mediastinal B‐cell lymphoma; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; RT, radiotherapy.